We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study.
- Authors
Rutkowski, S.; De Vleeschouwer, S.; Kaempgen, E.; Wolff, J. E. A.; Kühl, J.; Demaerel, P.; Warmuth-Metz, M.; Flamen, P.; Van Calenbergh, F.; Plets, C.; Sörensen, N.; Opitz, A.; Van Gool, S. W.; Kühl, J; Sörensen, N
- Abstract
Patients with relapsed malignant glioma have a poor prognosis. We developed a strategy of vaccination using autologous mature dendritic cells loaded with autologous tumour homogenate. In total, 12 patients with a median age of 36 years (range: 11-78) were treated. All had relapsing malignant glioma. After surgery, vaccines were given at weeks 1 and 3, and later every 4 weeks. A median of 5 (range: 2-7) vaccines was given. There were no serious adverse events except in one patient with gross residual tumour prior to vaccination, who repetitively developed vaccine-related peritumoral oedema. Minor toxicities were recorded in four out of 12 patients. In six patients with postoperative residual tumour, vaccination induced one stable disease during 8 weeks, and one partial response. Two of six patients with complete resection are in CCR for 3 years. Tumour vaccination for patients with relapsed malignant glioma is feasible and likely beneficial for patients with minimal residual tumour burden.
- Subjects
CANCER patients; TUMOR surgery; DENDRITIC cells; VACCINATION; CANCER relapse; GLIOMAS; GLIOMA treatment; DELAYED hypersensitivity; PILOT projects; RESEARCH; IMMUNIZATION; RESEARCH methodology; IMMUNOMODULATORS; EVALUATION research; COMPARATIVE studies; CANCER vaccines; COMBINED modality therapy; CEREBRAL edema
- Publication
British Journal of Cancer, 2004, Vol 91, Issue 9, p1656
- ISSN
0007-0920
- Publication type
journal article
- DOI
10.1038/sj.bjc.6602195